All Stories

  1. Mild cognitive impairment‐to‐Alzheimer's dementia progression risk: the contribution of the Interceptor project
  2. EEG network reorganization across Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies
  3. Microbiota-gut-brain axis dysregulation in Alzheimer’s disease and its modulation through probiotic supplementation
  4. Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA
  5. Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true?
  6. Risk factors of dementia in a cohort of individuals with mild cognitive impairment in the Italian Interceptor project
  7. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study
  8. Editorial: Neurophysiology in Alzheimer's disease and dementia, volume II
  9. Cognitive, psychological, and physiological effects of a web-based mindfulness intervention in older adults during the COVID-19 pandemic: an open study
  10. Microbiota from Alzheimer’s patients induce deficits in cognition and hippocampal neurogenesis
  11. Patients with Alzheimer’s disease dementia show partially preserved parietal ‘hubs’ modeled from resting-state alpha electroencephalographic rhythms
  12. Cortical network modularity changes along the course of frontotemporal and Alzheimer's dementing diseases
  13. The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations
  14. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel
  15. Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study
  16. Hyperconnectivity in Dementia Is Early and Focal and Wanes with Progression
  17. What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons
  18. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease
  19. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity
  20. Available and future treatments for atypical parkinsonism. A systematic review
  21. Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment
  22. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study
  23. Cerebral PET glucose hypometabolism in subjects with mild cognitive impairment and higher EEG high-alpha/low-alpha frequency power ratio
  24. The Vascular Impairment of Cognition Classification Consensus Study
  25. Possible Treatments of Atypical Parkinsonism
  26. Electroencephalography-driven approach to prodromal Alzheimer's disease diagnosis: from biomarker integration to network-level comprehension
  27. Editorial: Neurophysiology in Alzheimer's Disease and Dementia
  28. Involvement of mirror neuron system in prodromal Alzheimer's disease
  29. Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia
  30. Neurophysiology in Alzheimer's Disease and Dementia
  31. Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?
  32. Conversion of mild cognitive impairment patients in Alzheimer’s disease: prognostic value of Alpha3/Alpha2 electroencephalographic rhythms power ratio
  33. Association of EEG, MRI, and regional blood flow biomarkers is predictive of prodromal Alzheimer’s disease
  34. Mild Cognitive Impairment: Structural, Metabolical, and Neurophysiological Evidence of a Novel EEG Biomarker
  35. Alpha and Theta Rhythms Activity is Associated to Morpho- Structural and Perfusional Modifications in Subjects with Prodromal Alzheimer`s Disease
  36. Theta and alpha EEG frequency interplay in subjects with mild cognitive impairment: evidence from EEG, MRI, and SPECT brain modifications
  37. Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer’s disease
  38. Are there treatments for atypical parkinsonism? An update on actual options
  39. Understanding early dementia: EEG, MRI, SPECT and memory evaluation
  40. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study
  41. Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
  42. Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
  43. Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
  44. EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
  45. Electroencephalographic Upper/Low Alpha Frequency Power Ratio Relates to Cortex Thinning in Mild Cognitive Impairment
  46. Impairment of the Posterior Part of the Mirror Neurons System in Alzheimer’s Disease: Evidence from EEG Biomarkers
  47. The Contribution of EEG to the Diagnosis of Dementia
  48. Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series
  49. EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment
  50. Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio
  51. Relationship between EEG Alpha3/Alpha2 Ratio and the Nucleus Accumbens in Subjects with Mild Cognitive Impairment
  52. Analysis of Grey Matter in Thalamus and Basal Ganglia Based on EEG α3/α2 Frequency Ratio Reveals Specific Changes in Subjects with Mild Cognitive Impairment
  53. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD
  54. EEG markers are associated to gray matter changes in thalamus and basal ganglia in subjects with mild cognitive impairment
  55. Predictors of comprehensive stimulation program efficacy in patients with cognitive impairment. Clinical practice recommendations
  56. Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment
  57. Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease
  58. MCI patients’ EEGs show group differences between those who progress and those who do not progress to AD
  59. Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease
  60. Volumetric Differences in Mapped Hippocampal Regions Correlate with Increase of High Alpha Rhythm in Alzheimer's Disease
  61. EEG Changes are Specifically Associated with Atrophy in Amydala and Hippocampus in Subjects with Mild Cognitive Impairment
  62. Increasing Hippocampal Atrophy and Cerebrovascular Damage Is Differently Associated With Functional Cortical Coupling in MCI Patients
  63. Increase of Theta/Gamma and Alpha3/Alpha2 Ratio is Associated with Amygdalo-Hippocampal Complex Atrophy
  64. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide
  65. EEG Markers Discriminate Among Different Subgroup of Patients With Mild Cognitive Impairment
  66. Increase of theta/gamma ratio is associated with memory impairment
  67. Brain Vascular Damage of Cholinergic Pathways and EEG Markers in Mild Cognitive Impairment
  68. Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment
  69. Vascular damage and EEG markers in subjects with mild cognitive impairment
  70. Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders
  71. Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study
  72. Alpha rhythms in mild dements during visual delayed choice reaction time tasks: A MEG study
  73. Human cortical rhythms during visual delayed choice reaction time tasks
  74. Synchronization of gamma oscillations increases functional connectivity of human hippocampus and inferior-middle temporal cortex during repetitive visuomotor events
  75. Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study
  76. Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study
  77. Human cortical EEG rhythms during long-term episodic memory task. A high-resolution EEG study of the HERA model
  78. Individual analysis of EEG frequency and band power in mild Alzheimer's disease
  79. Cortical Networks Generating Movement-Related EEG Rhythms in Alzheimer's Disease: An EEG Coherence Study.
  80. Human cortical responses during one-bit short-term memory. A high-resolution EEG study on delayed choice reaction time tasks
  81. Transient human cortical responses during the observation of simple finger movements: A high-resolution EEG study
  82. Computerized processing of EEG–EOG–EMG artifacts for multi-centric studies in EEG oscillations and event-related potentials
  83. Shall I Move My Right or My Left Hand?
  84. Human Cortical Electroencephalography (EEG) Rhythms during the Observation of Simple Aimless Movements: A High-Resolution EEG Study
  85. Chapter 42 Quantitative EEG: modeling time, space, and phase of brain oscillatory activity
  86. Chapter 55 High resolution EEG of sensorimotor brain functions: mapping ERPs or mu ERD?
  87. Chronic bilateral electrical stimulation of the subthalamic nucleus for the treatment of advanced Parkinson's disease